Clover Biopharmaceuticals-B (Stock Code: 2197) announced on October 29, 2024 that its bivalent RSV candidate vaccine SCB-1019 achieved positive immunogenicity and safety data in Phase I clinical trials compared head-to-head with GSK's RSV vaccine AREXVY. The trial results showed that the geometric mean titers of neutralizing antibodies induced by SCB-1019 against RSV-A and RSV-B in elderly subjects were comparable to AREXVY, and the local adverse event incidence of SCB-1019 without adjuvant was significantly lower than AREXVY using AS01 adjuvant. In addition, the response trend of SCB-1019 to RSV-B specific antibodies was approximately 1.5 times higher. Based on these positive results, Clover Biopharmaceuticals plans to initiate further clinical trials in 2025 to evaluate the repeated dosing of SCB-1019 in RSV vaccine and respiratory tract combination vaccines applications. Shareholders and potential investors should proceed with caution.

Clover Biopharmaceuticals-B (Stock Code: 2197) announced on October 29, 2024 that its bivalent RSV candidate vaccine SCB-1019 achieved positive immunogenicity and safety data in Phase I clinical trials compared head-to-head with GSK's RSV vaccine AREXVY. The trial results showed that the geometric mean titers of neutralizing antibodies induced by SCB-1019 against RSV-A and RSV-B in elderly subjects were comparable to AREXVY, and the local adverse event incidence of SCB-1019 without adjuvant was significantly lower than AREXVY using AS01 adjuvant. In addition, the response trend of SCB-1019 to RSV-B specific antibodies was approximately 1.5 times higher. Based on these positive results, Clover Biopharmaceuticals plans to initiate further clinical trials in 2025 to evaluate the repeated dosing of SCB-1019 in RSV vaccine and respiratory tract combination vaccines applications. Shareholders and potential investors should proceed with caution.